In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actelion Braces For Tracleer Patent Cliff With New Drugs, New Data Standards

Executive Summary

Actelion is preparing for the patent loss on its leading PAH drug not simply with a new product, but by setting a new efficacy standard across the entire PAH community.

Advertisement

Related Content

Opsumit Label And Pricing Suggest Actelion’s Gamble Ready To Pay Off
Optimal Labeling For Opsumit Allows Actelion To Drop Promotion Of Tracleer
Actelion, Under Pressure To Diversify, Eyes Rare Disease Start-Up Ceptaris
Actelion Gets Early Benefits From Savings Plan, Awaits Opsumit Decision
Brand, Generic Disputes Over Access Move Beyond REMS Restrictions
COPD Market Snapshot: New Products, Limited Differentiation
Street Unsurprised By CRL For Oral Treprostinil, But United Therapeutics’ Stock Tumbles Anyway
Actelion CEO Seeks To Rebuild Investor Confidence As Pressure Builds On Tracleer
Actelion, GSK Scrap Sleep Drug Almorexant
Redefining Marketing and Development Innovation: GSK's Success with Advair

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel